Therapeutic Effects of hMAPC and hMSC Transplantation after Stroke in Mice

Abstract

Stroke represents an attractive target for stem cell therapy. Although different types of cells have been employed in animal models, a direct comparison between cell sources has not been performed. The aim of our study was to assess the effect of human multipotent adult progenitor cells (hMAPCs) and human mesenchymal stem cells (hMSCs) on endogenous neurogenesis, angiogenesis and inflammation following stroke. BALB/Ca-RAG 2−/− γC−/− mice subjected to FeCl3 thrombosis mediated stroke were intracranially injected with 2×105 hMAPCs or hMSCs 2 days after stroke and followed for up to 28 days. We could not detect long-term engraftment of either cell population. However, in comparison with PBS-treated animals, hMSC and hMAPC grafted animals demonstrated significantly decreased loss of brain tissue. This was associated with increased angiogenesis, diminished inflammation and a glial-scar inhibitory effect. Moreover, enhanced proliferation of cells in the subventricular zone (SVZ) and survival of newly generated neuroblasts was observed. Interestingly, these neuroprotective effects were more pronounced in the group of animals treated with hMAPCs in comparison with hMSCs. Our results establish cell therapy with hMAPCs and hMSCs as a promising strategy for the treatment of stroke.

Unveiling the effects of the secretome of mesenchymal progenitors from the umbilical cord in different neuronal cell populations

“…These effects were then related, by different authors, with the expression of growth factors such as brain derived neurotrophic factor (BDNF), nerve growth factor (NGF), insulin growth factor 1 (IGF-1), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), fibroblast derived growth factor 2 (FGF-2), stem cells factor (SCF) and glial derived neurotrophic factor (GDNF), as reviewed by Teixeira et al [12]. Similar phenomena were also reported in vivo [13][14][15][16]. In fact, Munoz et al [13] reported that the injection of bone marrow MSCs (BM-MSCs) in the mice hippocampus led to an increased neuronal differentiation, mediated by neurotrophic factors.…”

Clinical-Grade Multipotent Adult Progenitor Cells Durably Control Pathogenic T Cell Responses in Human Models of Transplantation and Autoimmunity

“…Human MAPCs can be distinguished from human MSCs on the basis of cell surface phenotype, cell size, transcriptional profile, cytokine production, differentiation potential and replicative capacity (6, 10, 34, 35). Previous work showed that murine MAPCs exert therapeutic immunomodulatory effects in the context of graft-versus-host disease prophylaxis, in MLR systems in vitro, and that human MAPCs prevented inflammation in a murine model of stroke, supporting a role for these cells in treating human immune-mediated diseases (36)(37)(38).…”

Variability in contrast agent uptake by different but similar stem cell types

“…[1][2][3][4][5] Due to their origin, bone marrow-derived stem cells are less debated from an ethical point of view than embryonic stem cells (ESCs). MSCs can differentiate into a number of mesenchymal phenotypes, including adipocytes, osteocytes, chondrocytes, and myocytes.…”